Carmichael Hill & Associates’s HUMANIGEN, INC. HGEN Stock Holding History

Carmichael Hill & Associates’s Portfolio HGEN Stock Details HGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30	Closed	-$5	–	810
2023 Q2	$5	Hold	30	–	–	﹤0.01%	789
2023 Q1	$5	Hold	30	–	–	﹤0.01%	779
2022 Q4	$4	Hold	30	–	–	﹤0.01%	782
2022 Q3	$0	Hold	30	–	–	﹤0.01%	881
2022 Q2	$0	Hold	30	–	–	﹤0.01%	883
2022 Q1	$0	Hold	30	–	–	﹤0.01%	848
2021 Q4	$0	Hold	30	–	–	﹤0.01%	846
2021 Q3	$0	Buy	+30	New	+$421	﹤0.01%	823

Other funds holding HGEN

TCM

Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

DWP

Daymark Wealth Partners Cincinnati, Ohio $3.18B AUM 23.46% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Carmichael Hill & Associates's HGEN Position: Q3 2023 in Review

Carmichael Hill & Associates sold out of HUMANIGEN, INC. (HGEN) in Q3 2023, closing a stake of 30 shares — an estimated $5 sold.

Carmichael Hill & Associates first reported a position in HGEN in Q3 2021 and held it in 8 quarters. The position peaked at $5 in Q2 2023. 3 funds tracked by Wall St. Rank hold HGEN as of Q3 2023.

Carmichael Hill & Associates reported no remaining HUMANIGEN, INC. position as of Q3 2023 after selling out during the quarter.
Carmichael Hill & Associates sold 30 HUMANIGEN, INC. shares in Q3 2023, an estimated $5.
Carmichael Hill & Associates first reported a position in HUMANIGEN, INC. in Q3 2021 and held it in 8 quarters.
Carmichael Hill & Associates's HUMANIGEN, INC. position peaked at $5 in Q2 2023.
3 funds tracked by Wall St. Rank held HUMANIGEN, INC. as of Q3 2023.

Based on Carmichael Hill & Associates's 13F filing for Q3 2023, filed 30 Oct 2023.